Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 322

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 322
---
 STOCKHOLDERS’ EQUITY

(Unaudited)

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated OtherComprehensive LossAccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar ValueBalance at December 31, 202431,050,448$31,050 —$— $265,650,362 $— $(224,295,186)$41,386,226 Issuance of common stock under at-the-market offering, net of issuance costs4,836,8044,837 —— 13,671,830 — — 13,676,667 Issuance of common stock through employee stock purchase plan98,45098 —— 133,794 — — 133,892 Stock-based compensation expense—— —— 1,692,267 — — 1,692,267 Net loss—— —— — — (15,046,132)(15,046,132)Balance at March 31, 202535,985,702$35,985 —$— $281,148,253 $— $(239,341,318)$41,842,920 Issuance of common stock upon exercise of stock options1,6042 —— 2,053 — — 2,055 Stock-based compensation expense—— —— 1,524,943 — — 1,524,943 Net loss—— —— — — (14,433,881)(14,433,881)Balance at June 30, 202535,987,306$35,987 —$— $282,675,249 $— $(253,775,199)$28,936,037 

9

Class A Common StockClass B Common StockAdditionalPaid-In CapitalAccumulated OtherComprehensive LossAccumulatedDeficitTotalStockholders' EquitySharesPar ValueSharesPar ValueBalance at December 31, 202329,271,629$29,272 —$— $253,806,267 $(778)$(163,258,578)$90,576,183 Issuance of common stock upon exercise of stock options229,299229 —— 732,229 — — 732,458 Issuance of common stock through employee stock purchase plan152,427152 —— 247